Laboute, Thibaut https://orcid.org/0000-0003-0870-1891
Zucca, Stefano https://orcid.org/0000-0002-8781-3295
Sial, Omar K.
Sharma, Mansi https://orcid.org/0009-0008-2358-1844
Brunori, Gloria
Singh, Shikha https://orcid.org/0000-0003-0266-4241
Nageswar, KV
Peng, Haiyong https://orcid.org/0000-0003-0312-1337
Rader, Christoph https://orcid.org/0000-0001-9955-3454
Becker, Jérôme AJ https://orcid.org/0000-0002-0039-0067
Le Merrer, Julie https://orcid.org/0000-0002-8670-4273
Singh, Appu K. https://orcid.org/0000-0002-2685-4018
Martemyanov, Kirill A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH105482)
Article History
Received: 19 June 2025
Accepted: 23 December 2025
First Online: 26 January 2026
Competing interests
: K.A.M. is a co-founder of EvoDenovo Inc., a startup company pursuing mGlyR as a drug target. The remaining authors declare no competing interests.